Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology
S Bergan, M Brunet, DA Hesselink… - Therapeutic drug …, 2021 - journals.lww.com
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
[HTML][HTML] Model-informed precision dosing: State of the art and future perspectives
IK Minichmayr, E Dreesen, M Centanni, Z Wang… - Advanced drug delivery …, 2024 - Elsevier
Abstract Model-informed precision dosing (MIPD) stands as a significant development in
personalized medicine to tailor drug dosing to individual patient characteristics. MIPD moves …
personalized medicine to tailor drug dosing to individual patient characteristics. MIPD moves …
WITHDRAWN: Executive Summary-The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients
WITHDRAWN: Executive Summary - The International Society for Heart and Lung
Transplantation (ISHLT) guidelines for the care of heart transplant recipients - ScienceDirect Skip …
Transplantation (ISHLT) guidelines for the care of heart transplant recipients - ScienceDirect Skip …
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update
This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …
Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug–drug interactions
L Elens, LJ Langman, DA Hesselink… - Therapeutic drug …, 2020 - journals.lww.com
Background: COVID-19 is a novel infectious disease caused by the severe acute respiratory
distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently …
distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently …
Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention
The immunosuppressive agent mycophenolate is used extensively in kidney transplantation,
yet dosing strategy applied varies markedly from fixed dosing (“one-dose-fits-all”), to …
yet dosing strategy applied varies markedly from fixed dosing (“one-dose-fits-all”), to …
Mycophenolate revisited
T van Gelder, DA Hesselink - Transplant International, 2015 - Wiley Online Library
The patent of mycophenolate mofetil (MMF) has expired, and for enteric‐coated
mycophenolate sodium (EC‐MPS), this will happen in 2017. In the twenty years these drugs …
mycophenolate sodium (EC‐MPS), this will happen in 2017. In the twenty years these drugs …
[HTML][HTML] Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology
S Udomkarnjananun, MI Francke… - Best Practice & …, 2021 - Elsevier
Immunosuppressive drugs have been key to the success of liver transplantation and are
essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune …
essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune …
The impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of mycophenolic acid: systematic review and meta-analysis
M Na Takuathung, W Sakuludomkan… - Clinical …, 2021 - Springer
Background Mycophenolic acid (MPA) is among the most commonly prescribed medications
for immunosuppression following organ transplantation. Highly variable MPA exposure and …
for immunosuppression following organ transplantation. Highly variable MPA exposure and …
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease
Mycophenolic acid (MPA), the active drug moiety of mycophenolate, is a potent
immunosuppressant agent, which is increasingly being used in the treatment of patients with …
immunosuppressant agent, which is increasingly being used in the treatment of patients with …